Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by dollarhunteron Oct 15, 2006 10:46am
130 Views
Post# 11505159

RE: Conference Call ....Thanks Brinkley.

RE: Conference Call ....Thanks Brinkley.I finally did get to hear the conference call. It appears that I had more than one pop up blocker system working on my computer. I'm a little mixed on the call as Peters put's an "everythings ok" spin on the pullout by Glaxo, which by the way is what we would expect him to do. But when all is said and done everyone here must agree that it sends a negative vibe back to shareholders. Still I've been here for years now and I think I'll wait and see what kind of financing the future holds because no matter who comes and goes [with regards to deeper bio pockets... Glaxo, Astra. etc.] if the money appears and the science proves more than potential, it will not matter who is involved as everybody will want in. Therefore as important as the financing is [and it is becoming more important as time winds down to next spring when they run out] if the science is not there it doesn't matter. Still long but mabey not quite as strong. Regards, DH
Bullboard Posts